Oncology Partner Buyout: Funding a Retiring Oncologist
An oncology partner buyout lets the remaining physicians in a group purchase the ownership interest of a partner who is retiring, relocating or stepping back. For many independent practices, it is the alternative to selling the entire practice to a hospital, oncology network or private equity group.
Done well, a buyout gives the departing physician fair value for years of work while keeping the practice independent for patients and staff. Done poorly, it can strain cash flow and relationships. This guide covers how buyouts are typically valued, structured and financed. Partnership agreements and tax rules vary, and nothing here is legal, tax, billing or compliance advice. Healthcare counsel and accountants should be involved from the start.
Why Buyouts Matter in Community Oncology
Many community oncology practices have senior physicians approaching retirement. When one of them leaves, the group faces a choice: buy out the partner internally or consider an outside sale. Outside buyers may offer attractive terms, but they often bring changes to governance, compensation and how care is delivered.
An internal buyout can preserve the group’s independence and culture. It requires a realistic price, a plan for patient care and financing the practice can support. Owners comparing paths may find our article on how to sell an oncology practice helpful.
Start With the Partnership Agreement
The first place to look is the existing partnership or shareholder agreement. Many agreements include buy-sell provisions that address:
- Events that trigger a buyout, such as retirement, disability or death
- How the departing partner’s interest will be valued
- Payment terms and timing
- Restrictive covenants and notice requirements
- Treatment of accounts receivable, drug inventory and real estate
If the agreement is outdated or vague, the partners may need to negotiate terms. Counsel should review any changes, and restrictive covenant enforceability varies by state.
Valuing the Departing Partner’s Interest
Valuation in oncology requires care because drug pass-through revenue can make a practice look larger than its true earnings. A fair buyout price generally reflects normalized earnings after market physician compensation, the departing partner’s share of equipment and inventory, and the effect the departure may have on patient volume.
Our article on oncology practice valuation explains the main drivers. An independent valuation may help reduce disagreements among partners. Our advisory and consulting services can also help groups think through succession planning.
Planning for Patient Care and Revenue
A retiring oncologist may manage a large patient panel and hold long-standing referral relationships. Before the buyout closes, the group should plan how those patients will be cared for and how referral sources will be introduced to other physicians.
Questions to consider include:
- Will the group recruit a new oncologist or advanced practice provider?
- Can existing physicians absorb additional patients?
- Will the departing partner work part-time during a transition?
- How will referral relationships be transferred?
Lenders will often ask the same questions, because the practice’s ability to repay depends on maintaining volume.
How an Oncology Partner Buyout Is Financed
Buyouts are usually funded by one or a combination of the following:
- Bank financing: the remaining partners or the practice borrow to pay the departing partner at closing
- Practice cash: available reserves, though oncology practices often need cash for drug inventory
- Seller financing: the departing partner accepts payments over time
- New partner buy-ins: a recruited physician purchases part of the interest
SBA 7(a) loans may be used for partner buyouts in some cases. Eligibility and terms depend on the business, the buyer, use of proceeds, program rules and lender review, and certain ownership-change transactions have specific program requirements. Conventional loans may also be available for established practices with strong cash flow.
If a seller note is part of the structure, lenders and programs may limit its terms, and seller notes are typically subordinate to the senior lender. Earnouts may also be restricted. Every loan is subject to approval, and nothing here is a commitment to lend.
Protecting Working Capital
Oncology practices depend on cash to fund buy-and-bill drug purchases. Using too much practice cash for a buyout can leave the group short when supplier invoices come due. Many groups pair buyout financing with an oncology working capital line of credit so they can keep operating comfortably during the transition.
Bringing in the Next Partner
A buyout often coincides with recruiting a new physician who may eventually buy in. Planning the buyout and the next buy-in together can help the group manage ownership shares and financing. Our guide to the oncology partnership buy-in explains what incoming physicians should know.
Tax Considerations
The way a buyout is structured, whether as a purchase of equity, a redemption by the practice or a mix of payments, can affect taxes for both the departing and remaining partners. Accountants and tax advisors should review the structure before terms are finalized.
Pitfalls to Avoid
- Waiting until a partner announces retirement to discuss valuation and terms
- Relying on an outdated formula in the partnership agreement
- Overlooking how the departure may affect patient volume and referrals
- Draining cash reserves needed for drug inventory
- Assuming payer contracts and enrollments will be unaffected by ownership changes, rather than confirming with counsel and billing professionals
Final Thoughts
An oncology partner buyout can honor a retiring physician’s contribution while keeping a community cancer practice independent. Clear agreements, a fair valuation, a plan for patients and referrals, and financing that leaves room for drug purchases and working capital can help the transition succeed for everyone involved.
US Medical Funding helps oncology groups finance partner buyouts and ownership transitions. Learn more about our oncology practice acquisition and buyout financing.
